| Date Filed | Type | Description |
| 10/12/2023 |
10-K
| Annual Report for the period ended June 30, 2023 |
| 10/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/29/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 09/27/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/15/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 06/16/2023 |
SC 13D/A
| Nantahala Capital Management, LLC reports a 19.7% stake in AYTU BIOPHARMA, INC. |
| 06/16/2023 |
SC 13G
| Stonepine Capital Management, LLC reports a 10% stake in Aytu BioPharma, Inc. |
| 06/12/2023 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 06/12/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 06/09/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 06/09/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/06/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 06/05/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 05/26/2023 |
SC 13D
| Nantahala Capital Management, LLC reports a 7.2% stake in AYTU BIOPHARMA, INC. |
| 05/11/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 05/01/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
8-K
| Quarterly results |
| 04/19/2023 |
8-K
| Quarterly results |
| 03/27/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 02/14/2023 |
SC 13G/A
| CVI Investments, Inc. reports a |
| 02/14/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 01/25/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 01/05/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...|
Docs:
|
"CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF AYTU BIOPHARMA, INC.",
"Aytu BioPharma Announces 1-for-20 Reverse Stock Split ENGLEWOOD, CO / January 5, 2023 / Aytu BioPharma, Inc. , a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced a 1-for-20 reverse stock split of its outstanding common stock, effective at 12:01 a.m. Eastern time on January 6, 2023. Beginning tomorrow, January 6, 2023, the Company's common stock will trade on a split-adjusted basis. At the Company's Special Meeting of Stockholders held on October 5, 2022, the Company's stockholders approved a proposal to amend the Company's Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio of up to one-for-twenty , as determined by the Company's Bo..." |
|
| 12/30/2022 |
8-K
| Quarterly results |
| 12/27/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/13/2022 |
8-K
| Quarterly results |
| 11/30/2022 |
8-K
| Quarterly results |
| 11/22/2022 |
8-K
| Quarterly results |
| 11/16/2022 |
8-K
| Quarterly results |
| 11/15/2022 |
8-K
| Quarterly results |
|